BioSpace News Archive

University of Mary Washington all-conference star and coach leads all-ages training and competitive play program at Washington region’s premier sports, wellness and active entertainment destination

The opioid crisis is a national public health crisis that is devastating individuals, families and communities across the country. Tragically, nearly 4,000 Canadians lost their lives in 2017 due to apparent opioid-related overdoses. Without increased access to effective, evidence-based treatment options, people with problematic substance

Peptide Logic announced that it was awarded a $ 2.9 million Small Business Innovation Research (SBIR) Phase II grant (R44DA042634) from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH)

The new clinic will provide access to more than 18 pediatric specialty care services in the North Sound region

For the sixth consecutive year, Medical Guardian Appears on the Inc. 5000, Ranking No. 2,681 with Three-Year Revenue Growth of 156%

Motionsoft announced that Jim Worthington will deliver the opening keynoted for the 5th annual Motionsoft Technology Summit in Washington, D.C.

Ortho Dermatologics, a division of Bausch Health Companies Inc., today announced it has resubmitted a New Drug Application to the U.S. Food and Drug Administration for DUOBRII™1 lotion in the treatment of plaque psoriasis.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that Merck, known as MSD outside the United States and Canada, initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration

What if the expense of healthcare insurance, your premium, became part of your investment portfolio? Whether you are an individual, small business or large corporation, a plan developed by a physician in suburban Atlanta, Georgia would make you a stock holder in your health insurance company.

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases.